Tag drug

Data from F. Farahmand Ghavi and colleagues advance knowledge in cochlear implants

Jul29

Researchers detail in ‘Corticosteroid-releasing cochlear implant: a novel hybrid of biomaterial and drug delivery system,’ new data in cochlear implants. According to recent research from Iran, "In this study, drug-eluting cochlear implant (CI) electrodes were prepared, and the amount of drug released was determined. Dexamethasone (DEX) (0.25-2% w/w, the weight percent of the final cured [...]

BRIEF: Azad seeks report on drug trials on poor [Hindustan Times, New Delhi]

Jul28

July 29BHOPAL The Centre and the Madhya Pradesh government have ordered separate probes into alleged illegal drug trials by doctors of Maharaja Yeshwantrao Hospital, Indore, on hundreds of patients.The probes followed a report in HT in its July 25 edition.Union Health Minister Ghulam Nabi Azad has asked Indian Medical Research Council (ICMR) director-general Dr [...]

Sanofi-Aventis warns on 2010 earns

Jul28

PARIS Sanofi-Aventis SA warned Thursday that its core earnings may fall up to 4 percent this year as a result of the U.S. Food and Drug Administration’s approval of a generic version of its Lovenox, an injected drug for preventing life-threatening blood clots.In a statement, the Paris-based drug maker says its so-called business net [...]

Global Health Ventures to Initiate Prototype Manufacturing of a Sublingual Anti-Anxiety Drug

Jul28

VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) 07/29/10 Global Health Ventures Inc. (OTCBB: GHLV) (the "Company"), a specialty pharmaceutical company today announced that it has signed an agreement with Carter Pharmaceutical of Toronto, Canada, to manufacture the prototype of its anti-anxiety drug "Relax-B". Together, the companies will manufacture about 10,000 pills for carrying [...]

Senate panel bans payments to delay generics

Jul28

WASHINGTON In a defeat for the powerful drug lobby, a Senate panel approved legislation to prohibit drug companies from paying generic drug makers to delay bringing less costly products to market.The Senate Appropriations Committee approved the measure, which was inserted into a spending bill that funds the Federal Trade Commission’s budget.The measure would ban [...]

Research from Zucker Hillside Hospital, Department of Psychiatry broadens understanding of schizophrenia

Jul27

Research findings, ‘D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis,’ are discussed in a new report. "Several lines of evidence suggest that antipsychotic drug efficacy is mediated by dopamine type 2 (D(2)) receptor blockade. Therefore, it seems plausible that variation in the DRD(2) gene is associated with clinical response to [...]

Ky. to get $2 million in drug company settlement

Jul27

FRANKFORT, Ky. Kentucky will receive nearly $2 million from a national settlement with a subsidiary of pharmaceutical manufacturer Johnson & Johnson over allegations the company illegally marketed an anti-seizure drug.Attorney General Jack Conway announced the state’s participation in the $75 million national settlement in a news release Wednesday. Kentucky’s share represents double the amount [...]

FDA Approves Drug for Chronic Drooling in Children

Jul27

SILVER SPRING, Md., July 28 /PRNewswire-USNewswire/ The U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years.(Logo: (Logo: Drooling is normal in infants. But a significant proportion of the developmentally disabled population experiences drooling caused primarily by [...]

FDA approve drool med 07 28

Jul27

To: HEALTH, MEDICAL, AND NATIONAL EDITORSContact: Elaine Gansz Bobo of the U.S. Food and Drug Administration, +1-301-796-7567, elaine.bobo@fda.hhs.gov, Consumer Inquiries: 888-INFO-FDASILVER SPRING, Md., July 28 /PRNewswire-USNewswire/ The U.S. Foodand Drug Administration today approved Cuvposa (glycopyrrolate) OralSolution to treat chronic severe drooling caused by neurologicdisorders in children ages 3 years to 16 years.(Logo: is [...]

FDA Advisory Committee Recommends US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes

Jul27

WILMINGTON, Del., July 28 /PRNewswire-FirstCall/ AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS).(Logo: )(Logo: )The Advisory Committee voted as follows:

Your Ad Here